) recently announced that the company settled its pending
), formerly known as Watson Pharmaceuticals.
The litigation was primarily related to Actavis' Abbreviated
New Drug Applications (ANDAs) for generic versions of Shire's
Attention Deficit Hyperactivity Disorder (ADHD) drug,
As per the settlement, Actavis is licensed to manufacture and
market its generic versions of Intuniv in the US from Dec 1, 2014
or earlier subject to certain limited circumstances.
Additionally, Shire is entitled to a 25% royalty on
gross profits from the sales within the 180 day period of
Meanwhile, the settlement also resolves outstanding litigation
against Watson's ANDA. The ANDA is still pending approval at the
US Food and Drug Administration (FDA).
We note that the FDA approved Actavis' ANDA for a generic
version of Intuniv in Oct 2012 and awarded Actavis 180 days of
ANDA market exclusivity.
The launch of Intuniv's generic by Actavis will impact Shire's
sales. We note that Intuniv is one of the three key drugs in the
ADHD market, the two others being Vyvanse and Adderall XR. As per
IMS Health, Intuniv generated sales of approximately $475 million
for the twelve months ending Jan 31, 2013.
Shire holds a strong position in the ADHD market. We note that
Vyvanse generated approximately 22% of total revenues in 2012.
Vyvanse (EU trade name: Elvanse) was approved in the EU in Dec
2012. Shire is currently developing Vyvanse for additional
indications such as the treatment of negative symptoms of
schizophrenia and binge eating disorder.
However, we are concerned about the increasing competition in
the ADHD market due to the entry of generics. Shire's share of
the US ADHD prescription market declined to 26.6% in Dec 2012
from 27.9% in the year-ago period.
Shire currently carries a Zacks Rank #4 (Sell). Right now,
stocks which look well placed include
WuXi PharmaTech (Cayman) Inc.
). Both stocks carry a Zacks Rank #1 (Strong Buy).
ACTAVIS INC (ACT): Free Stock Analysis Report
SHIRE PLC-ADR (SHPG): Free Stock Analysis
UCB SA (UCBJF): Get Free Report
WUXI PHARMATECH (WX): Free Stock Analysis
To read this article on Zacks.com click here.